دورية أكاديمية
Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature.
| العنوان: | Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature. |
|---|---|
| مؤلفون مشاركون: | European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), European Association for the Study of the Liver (EASL), North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), Latin‐American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (LASPGHAN), Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN), Pan Arab Society for Pediatric Gastroenterology and Nutrition (PASPGHAN), Commonwealth Association of Paediatric Gastroenterology & Nutrition (CAPGAN), Federation of International Societies of Pediatric Hepatology, Gastroenterology and Nutrition (FISPGHAN) |
| المصدر: | Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2024 May; Vol. 78 (5), pp. 1190-1196. Date of Electronic Publication: 2024 Mar 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 8211545 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-4801 (Electronic) Linking ISSN: 02772116 NLM ISO Abbreviation: J Pediatr Gastroenterol Nutr Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : [Hoboken, New Jersey] : Wiley Original Publication: [New York, N.Y.] : Raven Press, [c1982- |
| مواضيع طبية MeSH: | Terminology as Topic* , Non-alcoholic Fatty Liver Disease*/diagnosis , Non-alcoholic Fatty Liver Disease*/classification, Humans ; Child ; Pediatrics/standards ; Societies, Medical ; Fatty Liver/diagnosis ; Fatty Liver/classification ; Delphi Technique |
| مستخلص: | Nonalcoholic fatty liver disease (NAFLD) has been a commonly used term and diagnosis in paediatric hepatology, gastroenterology, and endocrinology clinics for over 30 years. A multisociety Delphi process has determined a new name "Steatotic Liver Disease" (SLD) as the overarching term for disorders associated with hepatic lipid accumulation. Our Societies give our support to steatotic liver disease as the best overarching term for use in our communities. Metabolic dysfunction-associated steatotic liver disease (MASLD) overcomes many of the shortcomings of the name NAFLD. Here, we highlight several points of the new nomenclature that are of particular importance for our community and their consequences for implementation including: diagnostic criteria, considering alternate diagnoses, practical implementation, research, advocacy, and education for paediatricians. As with all nomenclature changes, it will take a concerted effort from our paediatric societies to help integrate the optimal use of this into practice. (© 2024 The Authors. Journal of Pediatric Gastroenterology and Nutrition published by Wiley Periodicals LLC on behalf of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.) |
| References: | Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity. Liver Int. 2021;41:2295‐2307. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)‐associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864‐873. Rinella ME, Lazarus JV, Ratziu V, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542‐1556. doi:10.1016/j.jhep.2023.06.003. Schwimmer JB, Newton KP, Awai HI, et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non‐alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267‐1277. Eckel RH, Alberti KGMM, Grundy SM, et al. The metabolic syndrome. Lancet. 2010;375:181‐183. De Ferranti SD, Osganian SK. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diab Vasc Dis Res. 2007;4:285‐296. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta‐analysis. Am J Med. 2006;119:812‐819. European Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of coauthors. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease. Lancet Gastroenterol Hepatol. 2023;8:598‐600. Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510:84‐91. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130:1453‐1460. Bryan S, Afful J, Carroll M, et al. NHSR 158. National health and nutrition examination survey 2017–March 2020 pre‐pandemic data files. Centers for Disease Control and Prevention; 2021. Elisofon SA, Magee JC, Ng VL, et al. Society of pediatric liver transplantation: current registry status 2011‐2018. Pediatr Transplant. 2020;24:e13605. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461‐1465. Mandato C, Vajro P. Is the perfect screening of paediatric non‐alcoholic fatty liver disease still an unmet target? Acta Paediatr. 2022;111:2256‐2258. Shannon A, Alkhouri N, Carter‐Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr. 2011;53:190‐195. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54:700‐713. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nu. J Pediatr Gastroenterol Nutr. 2017;64:319‐334. Jia S, Zhao Y, Liu J, et al. Magnetic resonance imaging‐proton density fat fraction vs. transient elastography‐controlled attenuation parameter in diagnosing non‐alcoholic fatty liver disease in children and adolescents: a meta‐analysis of diagnostic accuracy. Front Pediatr. 2021;9:784221. Gu J, Liu S, Du S, et al. Diagnostic value of MRI‐PDFF for hepatic steatosis in patients with non‐alcoholic fatty liver disease: a meta‐analysis. Eur Radiol. 2019;29:3564‐3573. Hegarty R, Deheragoda M, Fitzpatrick E, et al. Paediatric fatty liver disease (PeFLD): all is not NAFLD: pathophysiological insights and approach to management. J Hepatol. 2018;68:1286‐1299. Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co‐sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528‐562. Mózes FE, Lee JA, Vali Y, et al. Performance of non‐invasive tests and histology for the prediction of clinical outcomes in patients with non‐alcoholic fatty liver disease: an individual participant data meta‐analysis. Lancet Gastroenterol Hepatol. 2023;8:704‐713. doi:10.1016/S2468-1253(23)00141-3. Yang R‐X, Zou Z‐S, Zhong B‐H, et al. The pathologic relevance of metabolic criteria in patients with biopsy‐proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: a multicenter cross‐sectional study in China. Hepatobiliary Pancreat Dis Int. 2021;20:426‐432. Ciardullo S, Carbone M, Invernizzi P, et al. Impact of the new definition of metabolic dysfunction‐associated fatty liver disease on detection of significant liver fibrosis in US adolescents. Hepatol Commun. 2022;6:2070‐2078. Mann JP, De Vito R, Mosca A, et al. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. Hepatology. 2016;63:745‐753. Allen AM, Lazarus JV, Younossi ZM. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. J Hepatol. 2023;79:209‐217. doi:10.1016/j.jhep.2023.01.026. |
| معلومات مُعتمدة: | None |
| فهرسة مساهمة: | Investigator: U Baumann; BGP Koot; E Fitzpatrick; J Mann; P Vajro; A Krag; D Shawcross; S Francque; T Böttler; BD Gold; JR Lightdale; M Mouzaki; N Rodriguez-Baez; R Kohli; VL Ng; D D'Agostino; G Porta; J Spolidoro; M Klünder-Klünder; R Vázquez-Frias; A Sibal; JS Ko; KM Kim; S Treepongkaruna; YH Ni; M El-Guindi; N Mohan; E Verduci; I Memon; M Bozo; M Godoy; M Orsi; M Aw; R Bandsma; S Ibrahim; S Xanthakos; S Treepongkaruna; T Mitsinikos Keywords: diagnostic algorithm; fatty liver disease; metabolism |
| تواريخ الأحداث: | Date Created: 20240326 Date Completed: 20240502 Latest Revision: 20240502 |
| رمز التحديث: | 20240502 |
| DOI: | 10.1002/jpn3.12156 |
| PMID: | 38529849 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!